Safety and Efficacy Maintenance Study of Quetiapine SR to Treat GAD Patients.
NCT ID: NCT00314210
Last Updated: 2009-03-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
575 participants
INTERVENTIONAL
2006-03-31
2007-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder
NCT00389064
Efficacy and Safety Study of Seroquel SR in the Treatment of Generalized Anxiety Disorder
NCT00322595
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Generalized Anxiety Disorder
NCT00329264
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder
NCT00329446
Quetiapine Fumarate Bipolar Maintenance Monotherapy
NCT00314184
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Quetiapine SR
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Martin Brecher, MD
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Mesa, Arizona, United States
Research Site
Peoria, Arizona, United States
Research Site
Phoenix, Arizona, United States
Research Site
Fresno, California, United States
Research Site
La Mesa, California, United States
Research Site
Oceanside, California, United States
Research Site
Redlands, California, United States
Research Site
Coral Springs, Florida, United States
Research Site
DeLand, Florida, United States
Research Site
Fort Myers, Florida, United States
Research Site
Gainsville, Florida, United States
Research Site
Hialeah, Florida, United States
Research Site
Jacksonville, Florida, United States
Research Site
North Miami, Florida, United States
Research Site
Orlando, Florida, United States
Research Site
Saint Petersberg, Florida, United States
Research Site
Atlanta, Georgia, United States
Research Site
Columbus, Georgia, United States
Research Site
Marietta, Georgia, United States
Research Site
Roswell, Georgia, United States
Research Site
Coeur d'Alene, Idaho, United States
Research Site
Hoffman Estates, Illinois, United States
Research Site
Libertyville, Illinois, United States
Research Site
Indianapolis, Indiana, United States
Research Site
Lafayette, Indiana, United States
Research Site
Valparaiso, Indiana, United States
Research Site
Prairie Village, Kansas, United States
Research Site
Owensboro, Kentucky, United States
Research Site
Paducah, Kentucky, United States
Research Site
Shreveport, Louisiana, United States
Research Site
Glen Burnie, Maryland, United States
Research Site
Boston, Massachusetts, United States
Research Site
Cambridge, Massachusetts, United States
Research Site
Pittsfield, Massachusetts, United States
Research Site
Saint Charles, Missouri, United States
Research Site
Piscataway, New Jersey, United States
Research Site
Cedarhurst, New York, United States
Research Site
New York, New York, United States
Research Site
Rochester, New York, United States
Research Site
The Bronx, New York, United States
Research Site
Avon Lake, Ohio, United States
Research Site
Beechwood, Ohio, United States
Research Site
Cincinnati, Ohio, United States
Research SIte
Middleburg Heights, Ohio, United States
Research Site
Toledo, Ohio, United States
Research Site
Oklahoma City, Oklahoma, United States
Research Site
Allentown, Pennsylvania, United States
Research Site
Havertown, Pennsylvania, United States
Research Site
Pittsburgh, Pennsylvania, United States
Research Site
North Charleston, South Carolina, United States
Research Site
Memphis, Tennessee, United States
Research Site
DeSoto, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Wichita Falls, Texas, United States
Research Site
Midvale, Utah, United States
Research Site
Richmond, Virginia, United States
Research Site
Brisbane, Queensland, Australia
Research Site
Everton Park, Queensland, Australia
Research Site
West Burleigh, Queensland, Australia
Research Site
Malvern, Victoria, Australia
Research Site
Prahran, Victoria, Australia
Research Site
Edmonton, Alberta, Canada
Research Site
Bathurst, New Brunswick, Canada
Research Site
Hamilton, Ontario, Canada
Research Site
Kingston, Ontario, Canada
Research Site
Orléans, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Waterloo, Ontario, Canada
Research Site
Gatineau, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Helsinki, , Finland
Research Site
Joensuu, , Finland
Research Site
Kuopio, , Finland
Research Site
Oulu, , Finland
Research Site
Pori, , Finland
Research Site
Seinäjoki, , Finland
Research Site
Turku, , Finland
Research Site
Berlin, , Germany
Research Site
Göttingen, , Germany
Research Site
Jena, , Germany
Research Site
Leipzig, , Germany
Research Site
München, , Germany
Research Site
Naumburg, , Germany
Research Site
Nuremberg, , Germany
Research Site
Schwerin, , Germany
Research Site
Siegen, , Germany
Research Site
Balassagyarmat, , Hungary
Research Site
Budapest, , Hungary
Research Site
Győr, , Hungary
Research Site
Gyula, , Hungary
Research Site
Kecskemét, , Hungary
Research Site
Nyíregyháza, , Hungary
Research Site
Bandung, West Java, Indonesia
Research Site
Jakarta, , Indonesia
Research Site
Cebu City, , Philippines
Research Site
Davao City, , Philippines
Research Site
Mandaluyong, , Philippines
Research Site
Manila, , Philippines
Research Site
Quezon City, , Philippines
Research Site
Moscow, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Saratov, , Russia
Research Site
Seoul, , South Korea
Research Site
Reading, Berkshire, United Kingdom
Research Site
Crawley, West Sussex, United Kingdom
Research Site
Blackpool, , United Kingdom
Research Site
Bolton, , United Kingdom
Research Site
Cardiff, , United Kingdom
Research Site
Chorley, , United Kingdom
Research Site
Coventry, , United Kingdom
Research Site
Glasgow, , United Kingdom
Research Site
Hamilton, , United Kingdom
Research Site
Liverpool, , United Kingdom
Research Site
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sheehan DV, Svedsater H, Locklear JC, Eriksson H. Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): data from a randomized-withdrawal, placebo-controlled maintenance study. J Affect Disord. 2013 Dec;151(3):906-13. doi: 10.1016/j.jad.2013.07.037. Epub 2013 Aug 16.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EUDRACT Number: 2005-005055-18
Identifier Type: -
Identifier Source: secondary_id
D1448C00012
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.